146 related articles for article (PubMed ID: 34720023)
1. Chronic inflammatory demyelinating polyneuropathy in Spain: a retrospective analysis of hospital incidence and medical costs.
Darbà J; Marsà A
Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):665-670. PubMed ID: 34720023
[TBL] [Abstract][Full Text] [Related]
2. Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients.
Alessandro L; Pastor Rueda JM; Wilken M; Querol L; Marrodán M; Acosta JN; Rivero A; Barroso F; Farez MF
J Peripher Nerv Syst; 2018 Sep; 23(3):154-158. PubMed ID: 29603827
[TBL] [Abstract][Full Text] [Related]
3. The economic burden of CIDP in the United States: A case-control study.
Divino V; Mallick R; DeKoven M; Krishnarajah G
PLoS One; 2018; 13(10):e0206205. PubMed ID: 30352101
[TBL] [Abstract][Full Text] [Related]
4. Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP).
Querol L; Crabtree M; Herepath M; Priedane E; Viejo Viejo I; Agush S; Sommerer P
J Neurol; 2021 Oct; 268(10):3706-3716. PubMed ID: 32583051
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands.
Broers MC; de Wilde M; Lingsma HF; van der Lei J; Verhamme KMC; Jacobs BC
J Peripher Nerv Syst; 2022 Sep; 27(3):182-188. PubMed ID: 35567759
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of chronic inflammatory demyelinating polyneuropathy in the South-Eastern area of Santiago, Chile.
Cea G; Idiáquez JF; Salinas R; Matamala JM; Villagra R; Stuardo A
J Clin Neurosci; 2020 Apr; 74():271-273. PubMed ID: 32067826
[TBL] [Abstract][Full Text] [Related]
7. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy.
Bril V; Blanchette CM; Noone JM; Runken MC; Gelinas D; Russell JW
J Diabetes Complications; 2016; 30(7):1401-7. PubMed ID: 27389526
[TBL] [Abstract][Full Text] [Related]
8. The economic burden and managed care implications of chronic inflammatory demyelinating polyneuropathy.
Owens GM
Am J Manag Care; 2018 Sep; 24(17 Suppl):S380-S384. PubMed ID: 30312033
[TBL] [Abstract][Full Text] [Related]
9. Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years.
Hiew FL; Ong JJ; Viswanathan S; Puvanarajah S
J Clin Neurosci; 2018 Apr; 50():203-207. PubMed ID: 29398193
[TBL] [Abstract][Full Text] [Related]
10. Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy.
Guptill JT; Bromberg MB; Zhu L; Sharma BK; Thompson AR; Krueger A; Sanders DB
Muscle Nerve; 2014 Jul; 50(1):47-51. PubMed ID: 24639235
[TBL] [Abstract][Full Text] [Related]
11. A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy.
Al-Zuhairy A; Sindrup SH; Andersen H; Jakobsen J
Muscle Nerve; 2020 Mar; 61(3):316-324. PubMed ID: 31793666
[TBL] [Abstract][Full Text] [Related]
12. Demyelinating neuropathy in diabetes mellitus.
Sharma KR; Cross J; Farronay O; Ayyar DR; Shebert RT; Bradley WG
Arch Neurol; 2002 May; 59(5):758-65. PubMed ID: 12020257
[TBL] [Abstract][Full Text] [Related]
13. Monocentric study of 28 cases of chronic inflammatory demyelinating polyneuropathy: first Tunisian study.
Mansour M; Rachdi A; Baradai N; Kacem A; Bedoui I; Mrissa R
Neurol Sci; 2022 Jan; 43(1):565-571. PubMed ID: 33945035
[TBL] [Abstract][Full Text] [Related]
14. Polyneuropathies and chronic inflammatory demyelinating polyradiculoneuropathy in multiple sclerosis.
Suanprasert N; Taylor BV; Klein CJ; Roforth MM; Karam C; Keegan BM; Dyck PJB
Mult Scler Relat Disord; 2019 May; 30():284-290. PubMed ID: 30870805
[TBL] [Abstract][Full Text] [Related]
15. Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment.
Pegat A; Boisseau W; Maisonobe T; Debs R; Lenglet T; Psimaras D; Azoulay-Cayla A; Fournier E; Viala K
J Peripher Nerv Syst; 2020 Jun; 25(2):162-170. PubMed ID: 32364302
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic criteria of chronic inflammatory demyelinating polyneuropathy in diabetes mellitus.
Lotan I; Hellman MA; Steiner I
Acta Neurol Scand; 2015 Oct; 132(4):278-83. PubMed ID: 25819084
[TBL] [Abstract][Full Text] [Related]
17. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Clinical Features, Diagnosis, and Current Treatment Strategies.
Reynolds J; Sachs G; Stavros K
R I Med J (2013); 2016 Dec; 99(12):32-35. PubMed ID: 27902997
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis.
Broers MC; Bunschoten C; Nieboer D; Lingsma HF; Jacobs BC
Neuroepidemiology; 2019; 52(3-4):161-172. PubMed ID: 30669140
[TBL] [Abstract][Full Text] [Related]
19. Hospital incidence and medical costs of polycythemia vera in Spain: a retrospective database analysis.
Darbà J; Marsà A
Expert Rev Pharmacoecon Outcomes Res; 2022 Sep; 22(6):965-970. PubMed ID: 35034517
[TBL] [Abstract][Full Text] [Related]
20. Clinical management of chronic inflammatory demyelinating polyneuropathy (CIDP) in Europe and India: An exploratory study.
Svačina MKR; Mehndiratta MM; Vedeler CA; Sharma Y; Bobylev I; Sprenger A; Remke G; Wüstenberg H; Klein I; Joshi A; Lehmann HC
J Neurol Sci; 2021 Aug; 427():117507. PubMed ID: 34130060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
